|
Symposium
[Free Online Symposium] Success Stories and Lessons Learned from Recent FDA Approvals: VOXZOGO (vosoritide) by BioMarin Pharmaceutical Inc.
Speakers:
Heather Wenzel, Anu Cherukuri, Yulan Qi, Michelle Fong
Organizers:
PBSS and California Life Sciences (CLS)
Date:
2022-07-27
Time:
10:00-13:00 Pacific Time
Registration fee:
0
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-07-24
(it will close sooner if the seating cap is reached)
About the Topic
VOXZOGO is a recombinant C-type natriuretic peptide (CNP) analog that has been modified to resist neutral endopeptidase degradation and enhance half-life. In 2021, VOXZOGO was approved for treatment of patients 2 years of age and older with Achondroplasia and open growth plates in the EU and under accelerated approval by US FDA to increase linear growth in patients 5 years and older with Achondroplasia whose growth plates are still open.
Achondroplasia is an inherited autosomal dominant condition caused by a gain-of-function mutation in the fibroblast growth factor receptor-3 gene (FGFR3), a negative regulator of endochondral bone formation. FGFR3 signaling via the MAPK pathway leads to decreased chondrocyte hypertrophy and matrix deposition and subsequently reduced skeletal growth at secondary ossification centers. VOXZOGO, similar to endogenous CNP, exerts its effect downstream of binding with NPR-B via PKGII, antagonizing the MAPK pathway at the level of Raf.
This presentation will discuss challenges and lessons learned during the development, marketing application review and approval process from the perspective of several project team members:
-
Interpreting Nonclinical Data for the Regulator (Heather Wenzel, MS, DABT, Associate Director, Pharmacology & Toxicology)
-
Clinical Pharmacology (Yulan Qi, PhD, Director, Clinical Pharmacology)
-
Value of the Integrated Summary of Immunogenicity or ISI (Anu Cherukuri, PhD, Senior
Scientist, Clinical Immunology)
-
[Regulatory Lessons Learned] (Michelle Fong, Executive Director, Regulatory Affairs)
Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event.
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|